A new coronivirus vaccine is in the works for the first time in the US.

It is expected to hit the market in early 2019.

The first vaccines are already available in Canada and the UK.

But the US is expected only to get one of the two, the National Institutes of Health (NIH) announced Thursday.

The National Institutes for Health (NIRS) said the vaccines are “still in development” and that it is “too early” to talk about specific production dates.

The agency also said it is not aware of any other coronaviruses.

There are two vaccines in the pipeline: the Cervarix vaccine, which is based on a human version of the virus, and the CNV-19 vaccine.

The new vaccine is already approved for use in people with HIV/AIDS in the United States.

It also has been approved in Africa, where it has been found to be effective in reducing the spread of the coronaviral coronaviremia.NIRs director, Dr. Gregory Thompson, said Thursday that there was still more to be learned about the vaccine, including how well it is protecting against the disease, and how it will work against people with other serious conditions, including those with cystic fibrosis and other lung conditions.

The US vaccine will be made available in six doses, each of which will contain a different vaccine strain.

The first dose is already available to people with pre-existing conditions.

The second dose is scheduled to be administered in early 2020.

The vaccine will also contain a second, more specific vaccine strain, the NIA said.

The NIH also announced a $6 billion fund to help with the new vaccine, called the National Vaccine Injury Compensation Fund (NVICF).

The fund will provide $6.5 billion in compensation for people who are injured by the new vaccines.

The money will be split among people with serious or life-threatening conditions who were treated in the hospital, and those who received the vaccine in the community.